Lion Bioscience AG

Drug Discovery Tools; Bioinformatics; Genomics. Lion Bioscience will offer bioinformatics and sequencing services based on modules. It offers an automated sequencing module, which claims higher throughput, higher reading lengths per clone and greater accuracy than commercially available systems. Lion also offers computational sequence anlysis software.

Last year, several scientists from the European Molecular Biology Laboratories(EMBL), a research organization in Heidelberg, Germany which supports 15 European states, were mulling over the idea of commercializing its bioinformatics work. At about the same time, a different group from the same scientific research organization was looking for ways to commercialize its sequencing technology. Yet another group, outside EMBL, planned to start a company in the field of genomics. The three parties began to talk and agreed to join forces. Lion Bioscience AG was born this winter to offer bioinformatics and sequencing services to pharmaceutical and industrial corporations and scientific research organizations. Lion is the first start-up built around EMBL technologies.

The founders were convinced that the combined groups would be in a better position to cover the full spectrum of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

Apellis’ Empaveli Expansion Underway In Rare Kidney Disease

 

The US FDA approved the complement C3 inhibitor for new indications in C3G and primary IC-MPGN, providing a new growth opportunity for Apellis.

CEO Underlines AstraZeneca’s Increasingly US-Centric Growth Plans

 

Its multibillion dollar investment demonstrates the importance of the US to AstraZeneca, with half of its targeted $80bn revenues by 2030 set to come from the country, Pascal Soriot said as it presented strong second-quarter results.

Analysts Not Impressed With Adaptimmune’s Survival Attempts

 
• By 

The company is getting just $55m from the sale of Tecelra and a couple of late-stage T-cell therapies to US WorldMeds.